AR044337A1 - Procedimiento para potenciar la cognicion usando ziprasidona - Google Patents
Procedimiento para potenciar la cognicion usando ziprasidonaInfo
- Publication number
- AR044337A1 AR044337A1 ARP040101652A ARP040101652A AR044337A1 AR 044337 A1 AR044337 A1 AR 044337A1 AR P040101652 A ARP040101652 A AR P040101652A AR P040101652 A ARP040101652 A AR P040101652A AR 044337 A1 AR044337 A1 AR 044337A1
- Authority
- AR
- Argentina
- Prior art keywords
- mammal
- formula
- ziprasidone
- human
- compound
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 title abstract 4
- 230000019771 cognition Effects 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 4
- 229960000607 ziprasidone Drugs 0.000 abstract 3
- 206010003805 Autism Diseases 0.000 abstract 2
- 208000020706 Autistic disease Diseases 0.000 abstract 2
- 206010012289 Dementia Diseases 0.000 abstract 2
- 208000036626 Mental retardation Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000009329 sexual behaviour Effects 0.000 abstract 2
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 206010022524 Intentional self-injury Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 208000005560 Self Mutilation Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000016571 aggressive behavior Effects 0.000 abstract 1
- 238000013019 agitation Methods 0.000 abstract 1
- 230000006399 behavior Effects 0.000 abstract 1
- 231100000867 compulsive behavior Toxicity 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Procedimiento de uso de los compuestos piperazinil-heterocíclicos de fórmula (1), para potenciar la cognición en un mamífero, incluyendo un ser humano, por ejemplo un mamífero aquejado de psicosis, autismo, demencia, o retraso mental, que comprende la administración de una cantidad eficaz de un compuesto de fórmula (1) (por ejemplo, ziprasidona) al mamífero. Procedimiento para reducir o mejorar en un mamífero, incluyendo un ser humano, aquejado de un trastorno o afección seleccionado entre autismo, retraso mental, trastorno obsesivo compulsivo, y demencia, los síntomas positivos (por ejemplo, agresión excesiva, conducta sexual desinhibida, conducta sexual inapropiada, agitación, conducta compulsiva tal como golpearse la cabeza, retorcerse los labios, automutilación, o conducta estereotípica) asociados a los trastornos o afecciones anteriormente mencionados, dicho procedimiento comprende la administración de una cantidad eficaz de un compuesto de fórmula (1) (por ejemplo, ziprasidona) al mamífero. Procedimiento para tratar el trastorno bipolar pediátrico en un mamífero, incluyendo un ser humano, dicho procedimiento comprende la administración de una cantidad eficaz de un compuesto de fórmula (1), (por ejemplo, ziprasidona) al mamífero. Los compuestos de la fórmula (1), se definen como sigue, o una sal de adición de ácidos farmacéuticamente aceptable del mismo, en la que Ar, n, X, e Y son como se han definido.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47137903P | 2003-05-16 | 2003-05-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR044337A1 true AR044337A1 (es) | 2005-09-07 |
Family
ID=33452442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040101652A AR044337A1 (es) | 2003-05-16 | 2004-05-14 | Procedimiento para potenciar la cognicion usando ziprasidona |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20050014764A1 (es) |
| EP (1) | EP1626722A1 (es) |
| JP (1) | JP2006528236A (es) |
| AR (1) | AR044337A1 (es) |
| BR (1) | BRPI0419067A (es) |
| CA (2) | CA2525323A1 (es) |
| MX (1) | MXPA05012325A (es) |
| TW (1) | TW200507847A (es) |
| WO (1) | WO2004100956A1 (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5080716B2 (ja) * | 2001-07-20 | 2012-11-21 | サイコジェニックス・インコーポレーテッド | 注意欠陥・多動性障害の治療 |
| CA2522708C (en) | 2003-04-29 | 2013-05-28 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
| AR053710A1 (es) * | 2005-04-11 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos |
| MY158766A (en) * | 2005-04-11 | 2016-11-15 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
| ES2761812T3 (es) | 2005-11-22 | 2020-05-21 | Nalpropion Pharmaceuticals Inc | Composición y métodos de aumento de la sensibilidad a la insulina |
| US20100222353A1 (en) * | 2006-01-27 | 2010-09-02 | Pfizer Products Inc. | Aminophthalazine derivative compounds |
| US7935706B2 (en) | 2006-02-23 | 2011-05-03 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| CA2666136A1 (en) * | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents |
| US20110294842A9 (en) * | 2006-10-12 | 2011-12-01 | Xenon Pharmaceuticals Inc. | Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain |
| RU2009117642A (ru) * | 2006-10-12 | 2010-11-20 | Ксенон Фармасьютикалз Инк. (Ca) | Применение спирооксиндоловых соединений в качестве терапевтических средств |
| AU2007319472B2 (en) | 2006-11-09 | 2013-01-17 | Nalpropion Pharmaceuticals Llc | Methods Of Administering Weight Loss Medications |
| CN101815518B (zh) | 2007-06-29 | 2013-01-09 | 埃莫里大学 | 用于神经保护的nmda受体拮抗剂 |
| SG195568A1 (en) * | 2008-05-09 | 2013-12-30 | Univ Emory | Nmda receptor antagonists for the treatment of neuropsychiatric disorders |
| WO2009158114A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
| HRP20150882T1 (hr) | 2008-10-17 | 2015-09-25 | Xenon Pharmaceuticals Inc. | Spirooksindolski spojevi i njihova upotreba kao terapijska sredstva |
| US8101647B2 (en) * | 2008-10-17 | 2012-01-24 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| NZ599334A (en) | 2009-10-14 | 2014-03-28 | Xenon Pharmaceuticals Inc | Synthetic methods for spiro-oxindole compounds |
| WO2011047173A2 (en) * | 2009-10-14 | 2011-04-21 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions for oral administration |
| EP2523557B1 (en) | 2010-01-11 | 2019-09-25 | Nalpropion Pharmaceuticals, Inc. | Methods of providing weight loss therapy in patients with major depression |
| CN102946859B (zh) | 2010-02-26 | 2016-03-02 | 泽农医药公司 | 用于局部给药的螺-羟吲哚化合物的药物组合物及其作为治疗剂的用途 |
| MX2012013197A (es) | 2010-05-12 | 2013-04-03 | Abbvie Inc | Inhibidores de indazol de cinasa. |
| PT2858640T (pt) | 2012-06-06 | 2020-06-30 | Nalpropion Pharmaceuticals Llc | Composição para utilização num método de tratamento de excesso de peso e obesidade em doentes com alto risco cardiovascular |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| AR103636A1 (es) | 2015-02-05 | 2017-05-24 | Teva Pharmaceuticals Int Gmbh | Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol |
| WO2016191316A1 (en) * | 2015-05-22 | 2016-12-01 | Stem Cell Theranostics, Inc. | Modulation of drug-induced cardiotoxicity |
| EP4493551A1 (en) | 2022-03-14 | 2025-01-22 | Slap Pharmaceuticals LLC | Multicyclic compounds |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX173362B (es) * | 1987-03-02 | 1994-02-23 | Pfizer | Compuestos de piperazinil heterociclicos y procedimiento para su preparacion |
| US4831031A (en) * | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| US4883795A (en) * | 1988-01-22 | 1989-11-28 | Pfizer Inc. | Piperazinyl-heterocyclic compounds |
| HU229057B1 (en) * | 1996-05-07 | 2013-07-29 | Pfizer | Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (-ziprasidone), its preparation and its use as dopamine d2 antagonist |
| ZA977967B (en) * | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
| IL125951A (en) * | 1997-09-05 | 2003-09-17 | Pfizer Prod Inc | A pharmaceutical composition comprising a piperazinyl-heterocyclic compound for treating tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal |
| IL127497A (en) * | 1997-12-18 | 2002-07-25 | Pfizer Prod Inc | Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders |
| US6387904B2 (en) * | 1998-05-18 | 2002-05-14 | Pfizer Inc | Method of treating glaucoma and ischemic retinopathy |
| EP1165027A1 (en) * | 1999-03-30 | 2002-01-02 | Lion Corporation | Hairdye composition of single preparation type containing an oxidase |
| JP2002541098A (ja) * | 1999-04-06 | 2002-12-03 | セプラコア インコーポレーテッド | ジプラシドン代謝産物を用いる神経弛緩薬性障害および関連障害を治療するための方法および組成物 |
-
2004
- 2004-05-05 CA CA002525323A patent/CA2525323A1/en not_active Abandoned
- 2004-05-05 MX MXPA05012325A patent/MXPA05012325A/es unknown
- 2004-05-05 BR BRPI0419067-0A patent/BRPI0419067A/pt not_active IP Right Cessation
- 2004-05-05 WO PCT/IB2004/001600 patent/WO2004100956A1/en not_active Ceased
- 2004-05-05 EP EP04731234A patent/EP1626722A1/en not_active Withdrawn
- 2004-05-05 CA CA002625837A patent/CA2625837A1/en not_active Abandoned
- 2004-05-05 JP JP2006530660A patent/JP2006528236A/ja active Pending
- 2004-05-14 AR ARP040101652A patent/AR044337A1/es unknown
- 2004-05-14 TW TW093113727A patent/TW200507847A/zh unknown
- 2004-05-14 US US10/846,797 patent/US20050014764A1/en not_active Abandoned
-
2008
- 2008-04-28 US US12/110,522 patent/US20080269246A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2625837A1 (en) | 2004-11-25 |
| WO2004100956A1 (en) | 2004-11-25 |
| BRPI0419067A (pt) | 2007-12-11 |
| US20050014764A1 (en) | 2005-01-20 |
| US20080269246A1 (en) | 2008-10-30 |
| EP1626722A1 (en) | 2006-02-22 |
| TW200507847A (en) | 2005-03-01 |
| CA2525323A1 (en) | 2004-11-25 |
| JP2006528236A (ja) | 2006-12-14 |
| MXPA05012325A (es) | 2006-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR044337A1 (es) | Procedimiento para potenciar la cognicion usando ziprasidona | |
| ATE360630T1 (de) | Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors | |
| CA2801241C (en) | Methods for treating bipolar disorder | |
| AR044007A1 (es) | Metodos para el tratamiento de la enfermedad de parkinson | |
| EA201490279A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| PL1697371T3 (pl) | Azabicykliczne heterocykle jako modulatory receptora kanabinoidowego | |
| PA8487601A1 (es) | Derivados biciclicos sustituidos utiles como agentes contra el cancer | |
| TW200726765A (en) | Triazolopyridine cannabinoid receptor 1 antagonists | |
| BRPI0415657A (pt) | derivados de alcanamina de diidrobenzofuranila como agonistas de 5ht2c | |
| EA200501098A1 (ru) | Антибактериальные агенты | |
| EA201001595A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| AR046272A1 (es) | Inhibidores de dipeptidil peptidasa iv | |
| BRPI0919020A2 (pt) | Uso de células de linhagem monocitária enriquecidas para tratar isquemia e para tratar angina pectoris | |
| CR7510A (es) | DERIVADOS DE [1-4] DIAZEPINO[6,7,1-iJ)] QUINOLONA COMO AGENTES ANTIPSICOTICOS Y CONTRA LA OBESIDAD | |
| AR069490A1 (es) | Agonistas de los receptores de glucocorticoides | |
| UY28279A1 (es) | Fenacilo 2 -hidroxi - 3 - diaminoalcanos | |
| EA200802412A1 (ru) | Терапевтические комбинации для сопровождающихся болью медицинских состояний | |
| NO20076357L (no) | Azabicykliske heterocykler som cannabinoid reseptor modulatorer | |
| CL2013003646A1 (es) | Compuestos derivados de trans-1-(3s.1r)-6-cloro-3-fenilindan-1-il)-1,2,2-trimetilpiperazina deuterados, con actividad en los receptores 5ht2, d1 y d2; proceso de preparacion; compuesto intermediario; composicion y combinacion farmaceutica; y su uso para el tratamiento de la psicosis, entre otros. | |
| AR015448A1 (es) | COMBINACIoN DE UN INHIBIDOR DE REABSORCIoN DE 5-HT CON UN ANTAGONISTA O AGONISTA PARCIAL DE H5-HT1B, PROCESO PARA SU PREPARACIoN, FORMULACIoN FARMACÉUTICA QUE LA CONTIENE, SU USO PARA PREPARAR MEDICAMENTOS PARA TRATAR TRASTORNOS AFECTIVOS Y KIT QUE CONTIENE DICHA COMBINACIoN | |
| NO20082181L (no) | Formuleringer av Fispemifen | |
| BR0306855A (pt) | Método para o tratamento de distúrbios cognitivos | |
| AR050043A1 (es) | Metodos para mejorar la biodisponibilidad y composicion farmaceutica para trastornos cardiovasculares | |
| GT200500214A (es) | Amidas del acido 5 y 6-aminoalquil indol-2-carboxilico 3-sustituidas y análogos relacionados como inhibidores de la caseína cinasa epsilon | |
| MX2010004313A (es) | Compuestos para inhibir la actividad de quinesina de la proteina de quinesina del huso. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |